- Home
- CDXS vs VOR Comparison
CDXS vs VOR Comparison
Compare CDXS & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDXS
- VOR
- Stock Information
- Founded
- CDXS 2002
- VOR 2015
- Country
- CDXS United States
- VOR United States
- Employees
- CDXS N/A
- VOR N/A
- Industry
- CDXS Major Chemicals
- VOR Biotechnology: Pharmaceutical Preparations
- Sector
- CDXS Industrials
- VOR Health Care
- Exchange
- CDXS Nasdaq
- VOR Nasdaq
- Market Cap
- CDXS 201.3M
- VOR 202.4M
- IPO Year
- CDXS 2010
- VOR 2021
- Fundamental
- Price
- CDXS $3.04
- VOR $2.76
- Analyst Decision
- CDXS Buy
- VOR Buy
- Analyst Count
- CDXS 2
- VOR 7
- Target Price
- CDXS $11.00
- VOR $3.77
- AVG Volume (30 Days)
- CDXS 910.6K
- VOR 46.8M
- Earning Date
- CDXS 08-07-2025
- VOR 08-07-2025
- Dividend Yield
- CDXS N/A
- VOR N/A
- EPS Growth
- CDXS N/A
- VOR N/A
- EPS
- CDXS N/A
- VOR N/A
- Revenue
- CDXS $49,815,000.00
- VOR N/A
- Revenue This Year
- CDXS $12.77
- VOR N/A
- Revenue Next Year
- CDXS $22.12
- VOR N/A
- P/E Ratio
- CDXS N/A
- VOR N/A
- Revenue Growth
- CDXS N/A
- VOR N/A
- 52 Week Low
- CDXS $1.90
- VOR $0.13
- 52 Week High
- CDXS $6.08
- VOR $3.29
- Technical
- Relative Strength Index (RSI)
- CDXS 69.54
- VOR 78.77
- Support Level
- CDXS $2.55
- VOR $2.25
- Resistance Level
- CDXS $2.91
- VOR $3.29
- Average True Range (ATR)
- CDXS 0.20
- VOR 0.52
- MACD
- CDXS 0.06
- VOR 0.18
- Stochastic Oscillator
- CDXS 96.17
- VOR 82.52
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.